3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Dermatologic
1
CNS
1
Conditions
Melanoma
3
Brain Neoplasms
2
Uveal Melanoma
1
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Noonan Syndrome 6
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, Large-Cell, Anaplastic
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Epoetin Alfa
3
Darbepoetin alfa
3
cobomarsen
2
Therapeutics
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Methotrexate
2
Early Intervention, Educational
2
Antilymphocyte Serum
2
vandetanib
1
tirbanibulin
1
sargramostim
1
motesanib diphosphate
1
imetelstat
1
fludarabine phosphate
1
fludarabine
1
ferrous sulfate
1
ferric gluconate
1
ethanolamine oleate
1
entrectinib
1
atezolizumab
1
Vorinostat
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Trimethoprim
1
Thiotepa
1
Sulfamethoxazole
1
Sucrose
1
Sodium Chloride
1
Sirolimus
1
Saline Solution, Hypertonic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
entrectinib
×
Dermatologic
×
Clear all
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled